Differential effect of agonistic anti-CD40 on human mature and immature dendritic cells: The Janus face of anti-CD40

Blood

Volumn 106, Issue 8, 2005, Pages 2806-2814

  De Herve, Marie Ghislaine De Goër ^b   Durali, Deniz ^b   Tran, Tú Anh ^b   Maigné, Gwénola ^b   Simonetta, Federico ^b   Leclerc, Philippe ^b   Delfraissy, Jean François ^b   Taoufik, Yassine ^a  

^a INSERM   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CD40 ANTIGEN; CD40 MONOCLONAL ANTIBODY; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CELL MATURATION; CELL SURVIVAL; DENDRITIC CELL; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 27144551974     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2004-12-4678     Document Type: Article

References (52)

1. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004;22:307-328.
2. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 1998;393:478-480.
3. + T-helper and a T-killer cell. Nature. 1998;393:474-478.
4. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
5. Tutt AL, O'Brien L, Hussain A, Crowther GR, French RR, Glennie MJ. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J Immunol. 2002;168:2720-2728.
6. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5:548-553.
7. Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood. 2003;102:1449-1457.
8. Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoe K. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb. J Immunol. 2000;164:1230-1235.
9. + cell responses. J Immunol. 2003;170:2727-2733.
10. van Mierlo GJ, den Boer AT, Medema JP, van et al. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc Natl Acad Sci U S A. 2002;99:5561-5566.
11. Bugajska U, Georgopoulos NT, Southgate J, et al. The effects of malignant transformation on susceptibility of human urothelial cells to CD40-mediated apoptosis. J Natl Cancer Inst. 2002;94:1381-1395.
12. Dallman C, Johnson PW, Packham G. Differential regulation of cell survival by CD40. Apoptosis. 2003;8:45-53.
13. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med. 2000;6:673-679.
14. Kedl RM, Jordan M, Potter T, Kappler J, Marrack P, Dow S. CD40 stimulation accelerates deletion of tumor-specific CD8(+) T cells in the absence of tumor-antigen vaccination. Proc Natl Acad Sci U S A. 2001;98:10811-10816.
15. + T cells in type 1 diabetes. Proc Natl Acad Sci U S A. 2004;101:9345-9350.
16. Zanelli E, Toes RE. A dual function for CD40 agonists. Nat Med. 2000;6:629-630.
17. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002;20:621-667.
18. Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells in the lymph node. Nat Immunol. 2003;4:733-739.
19. Moser M. Dendritic cells in immunity and tolerance-do they display opposite functions? Immunity. 2003;19:5-8.
20. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
21. McLellan A, Heldmann M, Terbeck G, et al. MHC class II and CD40 play opposing roles in dendritic cell survival. Eur J Immunol. 2000;30:2612-2619.
22. Kim KD, Choe YK, Choe IS, Lim JS. Inhibition of glucocorticoid-mediated, caspase-independent dendritic cell death by CD40 activation. J Leukoc Biol. 2001;69:426-434.
23. + dendritic cells. Proc Natl Acad Sci U S A. 1996;93:2588-2592.
24. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747-752.
25. Thornberry NA, Lazebnik Y. Caspases: enemies within. Science. 1998;281:1312-1316.
26. Smolewski P, Bedner E, Du L, et al. Detection of caspases activation by fluorochrome-labeled inhibitors: multiparameter analysis by laser scanning cytometry. Cytometry. 2001;44:73-82.
27. Tibbetts MD, Zheng L, Lenardo MJ. The death effector domain protein family: regulators of cellular homeostasis. Nat Immunol. 2003;4:404-409.
28. Rothe M, Sarma V, Dixit VM, Goeddel DV. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science. 1995;269:1424-1427.
29. Werneburg BG, Zoog SJ, Dang TT, Kehry MR, Crute JJ. Molecular characterization of CD40 signaling intermediates. J Biol Chem. 2001;276:43334-43342.
30. Roy N, Deveraux QL, Takahashi R, Salvesen GS, Reed JC. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 1997;16:6914-6925.
31. Fotin-Mleczek M, Henkler F, Samel D, et al. Apoptotic crosstalk of TNF receptors: TNF-R2-induces depletion of TRAF2 and IAP proteins and accelerates TNF-R1-dependent activation of caspase-8. J Cell Sci. 2002;115:2757-2770.
32. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 2002;22:207-220.
33. Algeciras-Schimnich A, Peter ME. Actin dependent CD95 internalization is specific for type I cells. FEBS Lett. 2003;546:185-188.
34. Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene. 2003;22:8634-8644.
35. Micheau O, Solary E, Hammann A, Dimanche-Boitrel MT. Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J Biol Chem. 1999;274:7987-7992.
36. Tang D, Lahti JM, Grenet J, Kidd VJ. Cycloheximide-induced T-cell death is mediated by a Fas-associated death domain-dependent mechanism. J Biol Chem. 1999;274:7245-7252.
37. Aragane Y, Kulms D, Metze D, et al. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J Cell Biol. 1998;140:171-182.
38. Chen Y, Lai MZ. c-Jun NH2-terminal kinase activation leads to a FADD-dependent but Fas ligand-independent cell death in Jurkat T cells. J Biol Chem. 2001;276:8350-8357.
39. Ashany D, Savir A, Bhardwaj N, Elkon KB. Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. J Immunol. 1999;163:5303-5311.
40. Leverkus M, Walczak H, McLellan A, et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood. 2000;96:2628-2631.
41. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 1995;182:1265-1273.
42. Schattner EJ, Elkon KB, Yoo DH, et al. CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med. 1995;182:1557-1565.
43. Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:3854-3859.
44. Muppidi JR, Siegel RM. Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol. 2004;5:182-189.
45. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21:461-465.
46. Mundle SD, Raza A. Defining the dynamics of self-assembled Fas-receptor activation. Trends Immunol. 2002;23:187-194.
47. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
48. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 2002;100:174-177.
49. Labeur MS, Roters B, Pers B, et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol. 1999;162:168-175.
50. Ichikawa HT, Williams LP, Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol. 2002;169:2781-2787.
51. Roth E, Schwartzkopff J, Pircher H. CD40 ligation in the presence of self-reactive CD8 T cells leads to severe immunopathology. J Immunol. 2002;168:5124-5129.
52. van Lieshout TW, Barrera P, Smeets RL, et al. Inhibition of TNF alpha during maturation of dendritic cells results in the development of semimature cells: a potential mechanism by which TNF alpha blockade exerts its beneficial effects in rheumatoid arthritis. Ann Rheum Dis. 2005;64:408-414.